Evidence map›Paper›PMID 42828195›Full record

ArticleNeuro-oncology advances

Prostate specific membrane antigen (PSMA) PET/CT for radiation planning and response assessment in intracranial high-grade gliomas.

Rituraj Upadhyay, Pavnesh Kumar, Divya Yadav, Bingfeng Tang, Erika Bello-Pardo, Hamid Mohtashami, Pawan Singh, Pierre Giglio, Kyle C Wu, James Brad Elder and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rituraj UpadhyayDepartment of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA.ORCID https://orcid.org/0000-0003-4079-1268
Pavnesh KumarDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Divya YadavDepartment of Diagnostic Imaging, Moffitt Cancer Center, Tampa, Florida, USA.
Bingfeng TangDepartment of Diagnostic Radiology and Nuclear Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Erika Bello-PardoOhio State University College of Medicine, Columbus, Ohio, USA.
Hamid MohtashamiDivision of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Pawan SinghDivision of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Pierre GiglioDivision of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0001-5165-0984
Kyle C WuDepartment of Neurosurgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0003-0009-5049
James Brad ElderDepartment of Neurosurgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Sasha BeyerDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Raj SinghDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Raju R RavalDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Evan M ThomasRenaissance Institute of Precision Oncology & Radiosurgery, Orlando, Florida, USA.
Chi ZhangDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Jana IvanidzeDepartment of Radiology, Weill-Cornell Medicine, New York, New York, USA.ORCID https://orcid.org/0000-0002-6470-5400
Joshua D PalmerDepartment of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0003-3311-0129

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate-specific membrane antigen (PSMA) expression has been demonstrated in the tumor microenvironment of high-grade gliomas (HGG). Here, we assessed the utility of PSMA-positron emission tomography (PET) imaging in patients with HGG for radiation therapy (RT) planning and in differentiating tumor progression from post-treatment changes. Methods: Patients with HGG (WHO grade 3-4) were included in our prospective PET imaging registry. Analysis was stratified into two cohorts based on clinical indication for PET-Cohort A: RT planning; and Cohort B: evaluation of suspected recurrence. PSMA avidity was quantified using standardized uptake value (SUV) measurements including absolute maximum SUV(SUVmax), and SUV ratio referencing right parotid (SUVRp), and superior sagittal sinus (SUVRsss). Results: Twenty-seven patients were included (Cohort A, Conclusions: PSMA PET avidity, particularly SUVmax, is higher in glioblastoma multiforme (GBM) patients with residual tumor or tumor progression. These findings suggest a potential role for PSMA PET in tumor delineation, aiding in comprehensive coverage of tumor volumes for radiation planning and response assessment to differentiate tumor progression and post-treatment changes.

Indexed as

glioblastomahigh-grade gliomasPSMA PET/CTradiation necrosistumor control

Identifiers

PMID42828195
PMCPMC13631924

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.